Affiliation:
1. Department of Haematology UCLH London UK
2. National Institute for Health Research Haematology Theme, Cardiovascular BRC, University College London Hospital/University College London London UK
Abstract
SummaryAcute thrombocytopenic purpura (TTP) may present at any stage of pregnancy and the puerperium. Without prompt diagnosis and therapy, serious maternal and fetal outcomes may result. ADAMTS13 replacement via plasma exchange and immunosuppression are the mainstay of treatment. There may be a role, however, for newer therapies, including caplacizumab and recombinant ADAMTS13. Differentiation of immune TTP and congenital TTP is vital, particularly to guide the management of subsequent pregnancies.
Funder
Takeda Pharmaceutical Company
British Heart Foundation
Alexion Pharmaceuticals